title: Malignant mixed Mullerian tumors.
abstract: Malignant mixed Mullerian tumours (MMMTs) are rare neoplasms, highly aggressive and with an extremely poor prognosis, usually arising in elderly postmenopausal women and presenting at an advanced stage. MMMTs derive from the mullerian mesodermus that differentiates in epithelial and stromal elements, both malignant elements. The clinic pathological features of 3 uterine MMMTs are reported here. The patients ranged in age from 25 to 69 years. The initial manifestations were mainly bloody discharge, abdominal pain and increase of the volume of the uterus. Treatment in 2 patients was hysterectomy with double ooforectomy, and resection of the pelvic mass was the treatment in the third case. Adjuvant radio chemotherapy was administrated in 2 of the 3 cases. Follow-up revealed recurrent pelvic tumour in 1 patient at 59 months, and breast metastases at 20 months in the second one. Because of the high incidence of recurrence and poor prognosis of these tumours, they should be studied and managed by a multidisciplinary team composed by surgeons, oncologists, radiotherapists and pathologists.
authors.affiliation: Department of General Surgery and Digestive System, University Hospital Ramón y Cajal, Madrid, Spain. jrtovar@wanadoo.es
authors.forename: J
authors.initials: J
authors.lastname: Ruiz Tovar
authors.forename: M E
authors.initials: ME
authors.lastname: Reguero Callejas
authors.forename: J I
authors.initials: JI
authors.lastname: Arano Bermejo
authors.forename: L F
authors.initials: LF
authors.lastname: Capote Armas
authors.forename: F
authors.initials: F
authors.lastname: González-Palacios Martínez
authors.forename: L
authors.initials: L
authors.lastname: Cabañas Navarro
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000556:secondary; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D005266:Femoral Neoplasms / Q000556:secondary; D006801:Humans; D007044:Hysterectomy; D007069:Ifosfamide / Q000008:administration & dosage; D007085:Ilium; D008875:Middle Aged; D018200:Mixed Tumor, Mullerian / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D016609:Neoplasms, Second Primary; D010052:Ovariectomy; D017239:Paclitaxel / Q000008:administration & dosage; D010166:Palliative Care; D010386:Pelvic Neoplasms / Q000556:secondary / Q000601:surgery; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012512:Sarcoma, Ewing; D013125:Spinal Neoplasms / Q000556:secondary; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery
chemical_list: D003520:Cyclophosphamide; D017239:Paclitaxel; D002945:Cisplatin; D007069:Ifosfamide